Asthma: Eosinophil Disease, Mast Cell Disease, or Both?

Allergy, Asthma & Clinical Immunology

Peter Bradding¹ 

[1] Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, UK

关键词: mast cell;    eosinophil;    asthma;   

Others  :  1083805
DOI  :  10.1186/1710-1492-4-2-84

【 授权许可】

   
2008 Canadian Society of Allergy and Clinical Immunology

【 参考文献 】

• [1]Holgate ST, Lackie PM, Davies DE, et al.: The bronchial epithelium as a key regulator of airway inflammation and remodelling in asthma. Clin Exp Allergy 1999, 29(Suppl 2):90-5.
• [2]Carroll NG, Mutavdzic S, James AL: Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax 2002, 57:677-82.
• [3]Ebina M, Yaegashi H, Chiba R, et al.: Hyperreactive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles. A morphometric study. Am Rev Respir Dis 1990, 141:1327-32.
• [4]Ebina M, Takahashi T, Chiba T, Motomiya M: Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am Rev Respir Dis 1993, 148:720-6.
• [5]Brightling CE, Ammit AJ, Kaur D, et al.: The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 2005, 171:1103-8.
• [6]Bradding P, Walls AF, Holgate ST: The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006, 117:1277-84.
• [7]Robinson DS, Hamid Q, Ying S, et al.: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326:298-304.
• [8]Bradding P, Roberts JA, Britten KM, et al.: Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994, 10:471-80.
• [9]Barnes PJ, Adcock IM: How do corticosteroids work in asthma? Ann Intern Med 2003, 139:359-70.
• [10]Huber HL, Koessler KK: The pathology of bronchial asthma. Arch Intern Med 1922, 30:689-95.
• [11]Beasley R, Roche WR, Roberts JA, Holgate ST: Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989, 139:806-17.
• [12]Bradding P, Walls AF, Church MK: Mast cells and basophils: their role in initiating and maintaining inflammatory responses. In Immunopharmacology of the respiratory system. Edited by Holgate ST. London: Academic Press; 1995:53-84.
• [13]Motojima S, Frigas E, Loegering DA, Gleich GJ: Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989, 139:801-5.
• [14]Ayars GH, Altman LC, McManus MM, et al.: Injurious effect of the eosinophil peroxide-hydrogen peroxide-halide system and major basic protein on human nasal epithelium in vitro. Am Rev Respir Dis 1989, 140:125-31.
• [15]Frigas E, Loegering DA, Solley GO, et al.: Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc 1981, 56:345-53.
• [16]Broide DH, Gleich GJ, Cuomo AJ, et al.: Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol 1991, 88:637-48.
• [17]Filley WV, Holley KE, Kephart GM, Gleich GJ: Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982, 3(2):11-6.
• [18]Bradding P, Feather IH, Wilson S, et al.: Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995, 151:1900-6.
• [19]Dubucquoi S, Desreumaux P, Janin A, et al.: Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin dependent secretion. J Exp Med 1994, 179:703-8.
• [20]Schmid-Grendelmeier P, Altznauer F, Fischer B, et al.: Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002, 169:1021-7.
• [21]Humbert M, Durham SR, Ying S, et al.: IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996, 154:1497-504.
• [22]Humbert M, Grant JA, Taborda-Barata L, et al.: High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996, 153:1931-7.
• [23]Ying S, Humbert M, Barkans J, et al.: Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997, 158:3539-44.
• [24]Frew AJ, Chan H, Lam S, Chan-Yeung M: Bronchial inflammation in occupational asthma due to Western red cedar. Am J Respir Crit Care Med 1995, 151:340-4.
• [25]Green RH, Brightling CE, Woltmann G, et al.: Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002, 57:875-9.
• [26]Wenzel SE, Schwartz LB, Langmack EL, et al.: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999, 160:1001-8.
• [27]Berry MA, Morgan A, Shaw DE, et al.: Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007, 62:1043-9.
• [28]O'Byrne PM: Cytokines or their antagonists for the treatment of asthma. Chest 2006, 130:244-50.
• [29]Leckie MJ, ten Brinke A, Khan J, et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-8.
• [30]Kips JC, O'Connor BJ, Langley SJ, et al.: Effect of SCH55700 a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167:1655-9.
• [31]Flood-Page P, Swenson C, Faiferman I, et al.: A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-71.
• [32]Flood-Page P, Menzies-Gow A, Phipps S, et al.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112:1029-36.
• [33]Green RH, Brightling CE, McKenna S, et al.: Asthma exacerbations and eosinophil counts. A randomised controlled trial. Lancet 2002, 360:1715-21.
• [34]Cruse G, Kaur D, Yang W, et al.: Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J 2005, 25:858-63.
• [35]Bradding P: Mast cells in asthma. In Asthma & rhinitis. Edited by Busse WW, Holgate ST. Boston: Blackwell Scientific Publications; 2000:319-38.
• [36]Howarth PH, Babu KS, Arshad HS, et al.: Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 2005, 60:1012-8.
• [37]Thomas PS, Yates DH, Barnes PJ: Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995, 152:76-80.
• [38]Thomas PS, Heywood G: Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002, 57:774-8.
• [39]Berry MA, Hargadon B, Shelley M, et al.: Evidence of a role of TNFa in refractory asthma. N Engl J Med 2006, 354:697-708.
• [40]Flint KC, Leung KB, Hudspith BN, et al.: Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen specific bronchoconstriction. Br Med J 1985, 291:923-6.
• [41]He S, Aslam A, Gaca MD, et al.: Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release. J Pharmacol Exp Ther 2004, 309:119-26.
• [42]Machado DC, Horton D, Harrop R, et al.: Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigenspecific IgE. Eur J Immunol 1996, 26:2972-80.
• [43]Frenz AM, Gibbs BF, Pearce FL: The effect of recombinant stem cell factor on human skin and lung mast cells and basophil leukocytes. Inflamm Res 1997, 46:35-9.
• [44]Coward WR, Okayama Y, Sagara H, et al.: NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J Immunol 2002, 169:5287-93.
• [45]Okumura S, Kashiwakura J, Tomita H, et al.: Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FceRI. Blood 2003, 102:2547-54.
• [46]Oskeritzian CA, Zhao W, Min HK, et al.: Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. J Allergy Clin Immunol 2005, 115:1162-8.
• [47]Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD: Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 2004, 114:174-82.
• [48]McCurdy JD, Olynych TJ, Maher LH, Marshall JS: Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003, 170:1625-9.
• [49]Kraneveld AD, Kool M, van Houwelingen AH, et al.: Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci USA 2005, 102:1578-83.
• [50]Eggleston PA, Kagey-Sobotka A, Schleimer RP, et al.: Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. Am Rev Respir Dis 1984, 130:86-91.
• [51]Brightling CE, Bradding P, Symon FA, et al.: Mast cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-705.
• [52]Bradding P, Holgate ST: Immunopathology and human mast cell cytokines. Crit Rev Oncol Haematol 1999, 31:119-33.
• [53]Sanmugalingam D, Wardlaw AJ, Bradding P: Adhesion of human lung mast cells to bronchial epithelium: evidence for a novel carbohydrate-mediated mechanism. J Leuk Biol 2000, 68:38-46.
• [54]Cairns JA, Walls AF: Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996, 156:275-83.
• [55]Yang W, Wardlaw AJ, Bradding P: Attenuation of human lung mast cell degranulation by bronchial epithelium. Allergy 2006, 61:569-75.
• [56]Cutz E, Levison H, Cooper DM: Ultrastructure of airways in children with asthma. Histopathology 1978, 2:407-21.
• [57]Brightling CE, Ward R, Goh KL, et al.: Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999, 160:406-10.
• [58]Brightling CE, Symon FA, Birring SS, et al.: Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 2003, 58:528-32.
• [59]Brightling CE, Symon FA, Birring SS, et al.: TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2002, 110:899-905.
• [60]Begueret H, Berger P, Vernejoux JM, et al.: Inflammation of bronchial smooth muscle in allergic asthma. Thorax 2007, 62:8-15.
• [61]Amin K, Janson C, Boman G, Venge P: The extracellular deposition of mast cell products is increased in hypertrophic airways smooth muscles in allergic asthma but not in nonallergic asthma. Allergy 2005, 60:1241-7.
• [62]Berger P, Girodet PO, Begueret H, et al.: Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. FASEB J 2003, 17:2139-41.
• [63]El-Shazly A, Berger P, Girodet PO, et al.: Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. J Immunol 2006, 176:1860-8.
• [64]Carroll NG, Mutavdzic S, James AL: Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002, 19:879-85.
• [65]Yang W, Kaur D, Okayama Y, et al.: Human lung mast cells adhere to human airway smooth muscle, in part, via tumor suppressor in lung cancer-1. J Immunol 2006, 176:1238-43.
• [66]Berger P, Compton SJ, Molimard M, et al.: Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchi. Clin Exp Allergy 1999, 29:804-12.
• [67]Berger P, Perng DW, Thabrew H, et al.: Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol 2001, 91:1372-9.
• [68]Brown JK, Jones CA, Rooney LA, et al.: Tryptase's potent mitogenic effects in human airway smooth muscle cells are via non-proteolytic actions. Am J Physiol Lung Cell Mol Physiol 2002, 282:L197-206.
• [69]Venkayya R, Lam M, Willkom M, et al.: The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyper-responsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol 2002, 26:202-8.
• [70]Brightling CE, Symon FA, Holgate ST, et al.: IL-4 and IL-13 are colocalised to mast cells within airway smooth muscle in asthma. Clin Exp Allergy 2003, 33:1711-6.
• [71]Brightling CE, Kaur D, Berger P, et al.: Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leuk Biol 2005, 77:759-66.
• [72]Cruse G, Duffy SM, Brightling CE, Bradding P: Functional KCa3.1 K+ channels are required for human lung mast cell migration. Thorax 2006, 61:880-5.